Role of Drug – Drug Interactions in the Efficacy and Safety of Clarithromycin Treatment for Helicobacter Pylori Eradication
- 作者: Serebrova S.Y.1,2, Kareva E.N.2,3, Eremenko N.N.1,2, Prokof’ev A.B.1,2, Kurguzova D.O.2, Drozdov V.N.2, Lazareva N.B.2, Komissarenko I.A.4, Starodubtsev A.K.2
-
隶属关系:
- Scientific Center for Expert Evaluation of Medicinal Products, Ministry of Health of the Russian Federation
- I. M. Sechenov First Moscow State Medical University (Sechenov University)
- N. I. Pirogov National Research Medical University
- A. I. Evdokimov Moscow State University of Medicine and Dentistry
- 期: 卷 53, 编号 8 (2019)
- 页面: 678-679
- 栏目: Article
- URL: https://bakhtiniada.ru/0091-150X/article/view/245941
- DOI: https://doi.org/10.1007/s11094-019-02061-5
- ID: 245941
如何引用文章
详细
Current risks from resistance, adverse drug reactions, and drug – drug interactions of clarithromycin used as a component of Helicobacter pylori eradication therapy are reviewed. The acid sensitivity of clarithromycin i responsible for the dependence of its pharmacological properties on the efficacy of proton-pump inhibitors, which could be one reason for the resistance of H. pylori to the macrolide. The potential for clarithromycin drug – drug interactions is related to its metabolism by CYP3A4 and strong inhibition of this enzyme.
作者简介
S. Serebrova
Scientific Center for Expert Evaluation of Medicinal Products, Ministry of Health of the Russian Federation; I. M. Sechenov First Moscow State Medical University (Sechenov University)
Email: kareva.en@1msmu.ru
俄罗斯联邦, 8/2 Petrovskii Blvd., Moscow, 127051; 8/2 Trubetskaya St., Moscow, 119991
E. Kareva
I. M. Sechenov First Moscow State Medical University (Sechenov University); N. I. Pirogov National Research Medical University
编辑信件的主要联系方式.
Email: kareva.en@1msmu.ru
俄罗斯联邦, 8/2 Trubetskaya St., Moscow, 119991; 1 Ostrovityanova St., Moscow, 117997
N. Eremenko
Scientific Center for Expert Evaluation of Medicinal Products, Ministry of Health of the Russian Federation; I. M. Sechenov First Moscow State Medical University (Sechenov University)
Email: kareva.en@1msmu.ru
俄罗斯联邦, 8/2 Petrovskii Blvd., Moscow, 127051; 8/2 Trubetskaya St., Moscow, 119991
A. Prokof’ev
Scientific Center for Expert Evaluation of Medicinal Products, Ministry of Health of the Russian Federation; I. M. Sechenov First Moscow State Medical University (Sechenov University)
Email: kareva.en@1msmu.ru
俄罗斯联邦, 8/2 Petrovskii Blvd., Moscow, 127051; 8/2 Trubetskaya St., Moscow, 119991
D. Kurguzova
I. M. Sechenov First Moscow State Medical University (Sechenov University)
Email: kareva.en@1msmu.ru
俄罗斯联邦, 8/2 Trubetskaya St., Moscow, 119991
V. Drozdov
I. M. Sechenov First Moscow State Medical University (Sechenov University)
Email: kareva.en@1msmu.ru
俄罗斯联邦, 8/2 Trubetskaya St., Moscow, 119991
N. Lazareva
I. M. Sechenov First Moscow State Medical University (Sechenov University)
Email: kareva.en@1msmu.ru
俄罗斯联邦, 8/2 Trubetskaya St., Moscow, 119991
I. Komissarenko
A. I. Evdokimov Moscow State University of Medicine and Dentistry
Email: kareva.en@1msmu.ru
俄罗斯联邦, 20/1 Delegatskaya St., Moscow, 127473
A. Starodubtsev
I. M. Sechenov First Moscow State Medical University (Sechenov University)
Email: kareva.en@1msmu.ru
俄罗斯联邦, 8/2 Trubetskaya St., Moscow, 119991
补充文件
